BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  BioLife Solutions Announces Executive Appointments to Support Integration of Acquired Companies

  BioLife Solutions, Inc. announced several executive appointments to further support the integration of Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, three companies acquired during 2019.

  December 2, 2019

   · 

  2 min read
• Policy

  CryoLife Receives CE Mark for E-nya Thoracic Stent Graft

  CryoLife, Inc., announced it has received CE Mark for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending thoracic aorta, including thoracic aortic aneurysms and dissections.

  December 2, 2019

   · 

  2 min read
• Business

  Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

  Puma Biotechnology, Inc., a biopharmaceutical company, and Pierre Fabre have agreed to extend the terms of the license agreement in which Puma granted Pierre Fabre exclusive rights to develop and commercialize NERLYNX® within Europe and part of Africa.

  December 2, 2019

   · 

  8 min read
• Biotech Bay

  Insera Announces Successful First-in-Human Treatment of Patient With Pulmonary Embolism Using the Cyclical Aspiration System, CLEAR

  Insera Therapeutics, Inc. announced that the first patient with acute pulmonary embolism, namely life-threatening blood clots blocking lung arteries, has been treated with its flagship cyclical aspiration system, CLEAR.

  December 2, 2019

   · 

  4 min read
• Business

  Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products

  Alteogen Inc. announced that it has entered into a non-exclusive global license agreement with a top 10 Global Pharmaceutical Company to use ALT-B4, Alteogen’s novel hyaluronidase-derived technology called Hybrozyme™ technology.

  December 2, 2019

   · 

  2 min read
• Resverlogix to Present at the Clinical Trials on Alzheimer’s Disease Congress 2019

  Subsequent conference call & webcast scheduled to present BETonMACE prespecified cognition assessment results

  December 2, 2019

   · 

  5 min read
• Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

  Adherence rates and screening intervals recognized as decisive elements of successful screening strategies

  December 2, 2019

   · 

  8 min read
• Pharm Country

  Fortress Biotech to Participate in December 2019 Investor Conferences

  Fortress Biotech, Inc. announced that the company will participate in two upcoming investor conferences.

  December 2, 2019

   · 

  3 min read
• Drug Development

  Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting

  Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence

  December 2, 2019

   · 

  7 min read
• Business

  Indivumed Announces Strategic Partnership with Biognosys

  Partnership Aims to Enhance Proteomics and Phosphoproteomics Insights in the IndivuType Multi-Omics Cancer Database

  December 2, 2019

   · 

  4 min read